Who are YM060's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BENZHYDROCODONE, NALBUPHINE HYDROCHLORIDE, XR-NTX 380 mg, intramuscular injection, standard opioid prescribing, Motrin and narcotic, Individualized oral morphine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ym060.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

YM060 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

YM060 (YM060) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: kappa opioid receptor antagonist. Area: Pain.

phase 3 kappa opioid receptor antagonist kappa opioid receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

YM060 (YM060) — Astellas Pharma Inc. YM060 is a selective and potent kappa opioid receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
YM060 TARGET	YM060	Astellas Pharma Inc	phase 3	kappa opioid receptor antagonist	kappa opioid receptor
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
XR-NTX 380 mg, intramuscular injection	XR-NTX 380 mg, intramuscular injection	University of Pennsylvania	marketed	Opioid receptor antagonist	Mu opioid receptor (primary); delta and kappa opioid receptors
standard opioid prescribing	standard opioid prescribing	Walter Reed National Military Medical Center	marketed	Opioid analgesic	Mu opioid receptor, delta opioid receptor, kappa opioid receptor
Motrin and narcotic	Motrin and narcotic	Cape Fear Valley Health System	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)
Individualized oral morphine	Individualized oral morphine	Children's Hospital of Fudan University	marketed	Opioid analgesic	Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (kappa opioid receptor antagonist class)

Astellas Pharma Inc · 1 drug in this class
QRxPharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). YM060 — Competitive Intelligence Brief. https://druglandscape.com/ci/ym060. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing